Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Crizotinib (approved) by the EMA in 2016 and by the FDA in 2016 for the treatment of Non-small-cell lung cancer (NSCLC) (ROS1 +) (1).
Crizotinib is an oral multikinase inhibitor that target ROS1receptor tyrosine kinases; it has been evaluated in advanced Non-small-cell lung cancer (NSCLC) (ROS1 +) in single-arm phase I–II clinical trials that supported regulatory approvals (2)